Sentinel lymph node biopsy in Japan survival benefi ts of ELND were not confi rmed, and ELND is becoming less common, especially in the United States.
In Japan, ELND had been accepted as the standard management in patients with primary tumors more than 3 mm in thickness. Intraoperative lymphatic mapping and selected lymphadenectomy (SLNB) have made it possible to determine the lymphatic fl ow from a primary tumor and to identify its sentinel lymph node(s) (SLNs) in the regional basin. 3, 4 This technique not only has lower morbidity than ELND but also permits more accurate and reliable staging. The new International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) melanoma staging system has incorporated the pathological evaluation in the SLN into the new staging criteria for melanoma 1 . Sentinel lymph node biopsy (SLNB) has been validated and is widely used as a staging tool for melanoma in Japan. Here, we mainly discuss data from Japanese patients and the present status of SLNB in Japan.
Melanoma in Japan
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Introduction
Lymph node metastasis is one of the most powerful predictors of recurrence and survival in patients with melanoma. 1 Therefore, elective lymph node dissection (ELND) has been widely used in the treatment of these patients. However, in several randomized controlled trials, overall Trends in anatomical site and Clark's subtype in Japan are shown in Tables 1 and 2 . 6 The foot is the most prevalent site of these lesions, and acral lentiginous melanoma is the most common type in Japanese patients. The prognosis of Japanese patients with melanoma is similar to that in Western countries. Five-year survival rates according to the new UICC/AJCC-TNM classifi cation in Japanese patients are as follows: stage 1A, 100%; IB, 91.1%; IIA, 81.5%; IIB, 70.1%; IIC, 64.6%; IIIA, 65.6%; IIIB, 61.8%; IIIC, 25.5%; and IV, 13.4% (n = 342). 7 
History of SLNB in Japan
Since 1988, several Japanese researchers have studied the lymphatic pathway and lymph node(s) drained from primary melanoma. 8 Morton et al. 3 reported the concept of the SLN and sentinel node navigation surgery in 1992, and this examination has since been used by dermatologists and plastic surgeons in Japan. There have been several Japanese reports regarding SLNB since the late 1990s. [9] [10] [11] [12] The fi rst meeting regarding SLNB for the management of melanoma in Japan was held in November 1999 ( 
Methods of SLNB in Japan
A combination method using blue dye injection, lymphoscintigraphy, and a handheld gamma probe has been widely used in Japan. However, the SLNB procedures, including patient selection, type of tracer used, and pathological evaluation, vary among hospitals. Therefore, the methods described here are mainly those adopted in an ongoing multicenter trial (Evaluation of safety and usefulness of sentinel node biopsy in patients with malignant melanoma; Grant-in-Aid for clinical trial from the Ministry of Health, Labour, and Welfare; Chief researcher, T. Saida: H19-clinical trial-013) and/or those used at our hospital.
Patient selection SLNB is performed essentially according to the standard procedure described by Cochran et al. 4 However, there are a few differences in procedures between Japan and Western countries. In Japan, the patients with melanoma usually visit directly or are referred to a dermatologist from their general practitioner without biopsy of the primary tumor. Preoperative biopsy is usually performed only when clinical diagnosis is diffi cult. Therefore, the patients generally receive both curative wide resection of the primary tumor and SLNB concurrently, without prior biopsy. Under these conditions, the thickness of the primary tumor is unknown before SLNB. Therefore, in practice, cases with suggested dermal invasion, even those less than 1 mm thick, often become candidates for SLNB. Preoperative high-frequency ultrasound may be used to determine the tumor thickness accurately (Fig. 2) . 13 Dermoscopy is also useful to predict dermal invasion.
14 On the other hand, it is still controversial whether patients with lesions more than 4 mm in thickness should undergo SLNB, because historical data indicate that these patients have a high rate of occult systemic metastasis at the time of initial presentation. The European Association of Nuclear MedicineEuropean Organization for Research and Treatment of Cancer (EANM-EORTC) recommend that SLNB should be offered to patients with clinically localized disease, including melanomas more than 4 mm in thickness. 15 At the institutions included in the H19-clinical trial-013, patients with melanomas more than 4 mm thick were often candidates for SLNB.
Lymphatic mapping and node biopsy
Patients with suitable indications for SLNB undergo lymphoscintigraphy 1 day before or on the day of surgery. Radionuclide is injected intradermally around the primary site. Tc 99m -tin colloid and Tc 99m -phytate, which have particle sizes ranging from 400 to 5000 nm and from 200 to 1000 nm, respectively, are frequently used as radioactive tracers in Japan. Detection rates with these radionuclides are high, and were reported as 95.2% for tin colloid (99/104) and 98.7% (151/153) for phytate (H19-clinical trial-013). The combination of both single-photon emission computed tomography and computed tomography (SPECT-CT) allow accurate visualization of the SLN (s) and are especially useful in the head and neck region. 16 Based on the results of lymphoscintigraphy and a handheld gamma probe survey, the site with the highest level of radioactivity is marked with a pen. After anesthesia, patent blue violet or indigo carmine is injected intradermally around the primary tumor and the area is gently massaged to enhance lymphatic fl ow. Then an incision is made over the marked skin site and the SLN is identifi ed with the handheld gamma probe and visualized by blue dye. Some hospitals use fl uorescent indocyanine green, which allows visualization of the SLN with an infrared camera. A clinical trial to evaluate the effi cacy of this method is currently underway. Preliminary results indicate a 100% detection rate of SLN by this method in 28 cases (N. Yamazaki; Dermatology, National Cancer Center Hospital: H19-clinical trial-013). There is no consensus on a practical defi nition of SLN. In our study, a lymph node showing more than onetenth the radioactivity of the most active node is defi ned as the SLN, although sometimes low-activity lymph nodes near the SLN may also be excised.
Pathological evaluation
The excised SLN is fi xed in formalin, embedded in paraffi n, and processed for pathological examination according to the method of Cochran et al. 4 The presence of metastases is evaluated using serial sections stained with hematoxylin and eosin (H&E) and the murine monoclonal antibodies Mart1 (MelanA), HMB-45, and S-100 for immunohistochemical evaluation. If the SLN contains metastases, curative lymph node dissection (CLND) is recommended and performed in the majority of cases. Genetic analysis, using reverse-transcriptase polymerase chain reaction (RT-PCR) to detect much earlier metastasis in SLN, has been performed since the late 1990s. 17 A clinical trial is currently underway to evaluate the benefi ts of this approach (Genetic diagnosis of sentinel lymph nodes in malignant melanoma; Grant-in-Aid for clinical trial from the Ministry of Health, Labour, and Welfare; chief researcher, Y. Moroi; H19-clinical trial-018).
In Japan, dermatologists and some plastic surgeons are generally involved in almost all the steps described above, including injection of tracer, marking of hot spots, lymph node biopsy, resection of the primary tumor, pathological evaluation, and even CLND at some hospitals with radiologists, pathologists, and surgeons.
SLNB data in Japanese patients
There have been no large-scale studies of melanoma, such as randomized controlled trials, in Japan due to its low incidence. Therefore, the data we present is mainly from the studies carried out by the Melanoma Study Group of the Health and Labour Science Research Grants from the Ministry of Health, Labour, and Welfare (MSG 11-7, 15-10, 19-7) and the H19-clinical trial-013.
Detection rate
Data from the MSG 11-7 and MSG 15-10 studies are shown in Table 3 . From 1999 to 2002 (MSG 11-7 study), vital blue dye only was mainly used to detect SLN. Preoperative lymphoscintigraphy was used in one-quarter of the patients. In this study, the numbers of SLNs detected were: 1 in 70% of patients, 2 in 23%, and more than 3 in 7%. The detection rate was infl uenced by the location of the primary site, and was 93% in the groin region, 88% in the axilla, and 78% in the head and neck. The same trend was reported by Takahashi et al., 18 but detection rates in their study, in which a combination of blue dye and radionuclide was used, were 97% in the groin, 96% in the axilla, and 89% in the neck region.
The MSG 11-7 study reported that metastasis in the SLN was detected in 25% (65/261) of cases. This study included 130 patients undergoing both ELND and intraoperative lymphatic mapping, which was performed during training for the SLNB procedure. In 3 of these 130 patients, metastasis was detected in non-SLN, but not in SLN showing radioactivity and/or staining with blue dye. Therefore, the false-negative rate in this study was 2.3%, which confi rmed the accuracy of SLNB. Data from 2003 to 2007 in the MSG 15-10 study showed that the combination method with blue dye, lymphoscintigraphy, and the handheld gamma probe had been widely used (Table 3 ). The detection rate increased from 85% with blue dye only to more than 98% with the combination method. Noro et al. 19 reported similar observations, in which the SLN was detected in 82.4% of cases with blue dye only, but in 100% with blue dye and radionuclide. Recently, an interim report (H19-clinical trial-013) showed that the detection rate with the combination method was 97.5%. These results were similar to those reported previously in Western countries.
Metastatic rate
The relationship between the metastatic rate in SLNs and T categories, investigated in a study by Uhara et al., 20 is shown in Figs. 3-5 . This study was a retrospective review of 259 patients who underwent successful SLN mapping and biopsy at 13 facilities in Japan between 2003 and 2006. Similar to fi ndings in a previous study, the metastatic rate was strongly related to the T category (Fig. 3) . The relationship between metastatic rate and Breslow's tumor thickness is shown in Fig. 4 . Metastasis was detected in 4 T1a cases excluded as candidates for SLNB according to the UICC/ AJCC staging criteria. Tumor thicknesses in these 4 cases were 1.0, 0.8, 0.55, and 0.50 mm. Ulceration increased the rate of metastasis and there was a signifi cant difference between the group except for over 4 mm thick and the group including all invasive cases (P < 0.001; Fig. 5 ).
SLNB and ELND
The clinical benefi t of ELND for patients with melanoma has been controversial. In several randomized controlled trials, overall survival benefi ts conferred by ELND were not confi rmed, and, especially in the United States, ELND has not been performed since these fi ndings were published. However, in Japan, ELND has been used continuously as standard management for patients with primary tumors more than 3 mm thick. Tsutsumida et al. 21 compared the outcome of SLND (n = 30) and ELND (n = 72) in Japanese patients and reported that there was no signifi cant difference in the 3-year disease-free survival rate between the two groups. ELND has now been replaced by SLNB at many hospitals in Japan.
Lymphatic drainage pathways
We can obtain some interesting information through SLNB. For example, the foot is the most prevalent site of melanoma in Japanese patients. There are two main lymphatic routes from the sole of the foot; the fi bular route to the popliteal node and the tibial route to the groin node. Clinical experience has shown that popliteal node metastasis is rarely observed in patients with melanoma of the foot; Thompson et al. 22 reported that the rate was less than 1%. The reason for this rare metastatic location can be inferred from lymphatic visualization with blue dye. Drainage from the sole of the foot usually passes across the plantar or the dorsal surface of the foot and runs to the dorsal foot branch of the great saphenous vein located on the tibial side before changing direction and passing along the vein (Fig. 6) . 23 Lai et al. 24 reported that the popliteal node received lymphatic fl ow from a wide region of the foot; the skin of the dorsum of the foot, sole of the heel, and the medial heel. However, in our experience, drainage from the foot to the popliteal node does not occur often, except in cases in which groin node metastasis has already occurred.
Public health insurance system and SLNB in Japan SLNB is becoming the standard form of care in early-stage melanoma. Pathological evaluation of the SLN is now necessary for UICC/AJCC staging. In Japan, SLNB has been performed as an experimental examination, and has not yet been approved by the Japanese public health insurance system. However, in 2003, the Ministry of Health, Labour, and Welfare classifi ed SLNB as an "advanced medical treatment." Due to recent progress in medical technology, many advanced treatment methods should be considered candidates for standard care. The aim of "advanced medical treatments" is to evaluate the effi cacy and toxicity of new techniques used as standard methods around the world. As technology-related costs in advanced medical treatments are not covered by public health benefi ts, the patient must pay the costs. However, under the current system, doctors can provide both medical care covered and not covered by insurance at the same time, which is usually prohibited in Japan.
Conclusions
The interim results of the Multicenter Selective Lymphadenectomy Trial (MSCT-I) have indicated that early detection of regional lymph node metastasis and subsequent resection contributed to the improvement of disease-free survival, although there has been some critical discussion of the analysis of the results. [25] [26] [27] [28] [29] SLNB has been validated for more than a decade and is now widely performed in the staging of melanoma in Japan. Recent studies showed that approximately 90% of university hospitals and several cancer hospitals routinely performed SLNB and that half of all melanoma patients received this examination. Recent detection rates of SLN have increased to more than 95% with the combination method using blue dye, lymphoscintigraphy, and a handheld gamma probe. In a multicenter study in Japan, 20 the metastatic rate in the SLN was closely related to tumor thickness and ulceration of the primary tumor. In Japan, SLNB is performed as part of a clinical trial, and is not covered by public health insurance. To gain approval by the public health insurance system, some clinical trials are currently ongoing to evaluate the utility and safety of SLNB and to clarify whether the quantitative assessment of tumor burden in the SLN could become a predictive prognostic factor or an indicator for the performance of CLND.
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